Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eucure Biopharma Licenses Antibody to Syncromune for Personalized Cancer Therapy

publication date: Oct 18, 2022

Eucure (Beijing) Biopharma licensed its YH002, an anti-OX40 humanized IgG1 agonistic antibody, for use with Syncromune’s Syncrovax™ technology. Syncromune, a Fort Lauderdale company, describes the Syncrovax™ platform as a personalized cancer therapy aimed at optimizing intratumoral immunotherapies for metastatic solid tumor cancers. The platform aims to synchronize the timing and location of tumor antigen release with the activation of immune cells. Eucure will receive up to hundreds of millions of US dollars from upfront and milestone payments, plus royalties. Syncromune will have exclusive rights to YH002 for the combination, while Eucure retains other global rights. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital